The Food and Drug Administration (FDA) is currently evaluating a new influenza vaccine developed by Moderna, referred to as mFlusiva. This vaccine is specifically aimed at older Americans and is being reviewed in anticipation of the upcoming winter flu season.
✓ AI-Debiased Article
14
Public broadcaster
L
R
No clear lean
✓ verified
Why this rating? · 1 signal
Signals flagged in the original
- framing: first-of-its-kind
Analyzed by our bias model Full breakdown ↓
FDA panel reviews Moderna's mRNA flu vaccine for older Americans
The FDA is assessing Moderna's mRNA-based flu vaccine, mFlusiva, which targets older Americans. The evaluation is taking place ahead of the winter flu season.
Companies
Moderna
Annotating as
No note attached
on this article.
Read next
FDA Committee Recommends Moderna's mRNA Influenza Vaccine for Adults 50 and Over
NPR — Top Stories
FDA Advisory Panel Recommends Approval of Moderna's mRNA Flu Vaccine for Older Adults
The Hill
FDA Advisors Support Approval of Moderna's mRNA Flu Vaccine
Ars Technica
FDA Panel Reviews Moderna's mRNA Flu Vaccine for Older Adults
Guardian — US
Bias Analysis
Bias score
14/100
wirepublicmainstream
flavoredpartisanadvocacy
Inflammatory language
10/100
Bias Indicators Removed
- ✕ framing: first-of-its-kind
Original vs. Neutral
Original Headline
FDA panel backs first-of-its-kind flu vaccine using mRNA technology
Neutral Headline
FDA panel reviews Moderna's mRNA flu vaccine for older Americans